Viking Therapeutics (VKTX) surged to a 5-year high today. Jenny Horne discusses VKTX as it shared positive phase 1 data for obesity treatment. She talks about how the VK2735 treatment is given as an oral tablet daily. The CEO notes that the company looks forward to exploring higher doses over a longer treatment window in phase 2 trial. Tune in to find out more about the stock market today.
28 Mar 2023
Next Gen Investing
05 Jul 2023
Morning Trade Live
08 Aug 2023
Trading 360
10 Jul 2023
Market On Close
07 Jul 2023
Morning Trade Live
10 Jul 2023
Morning Trade Live
15 Sep 2023